Companion Diagnostic

One of the keys to diagnosing and treating Glioblastoma is having a full picture of the disease. Knowing which of the four GBM subtypes each patient has is a key piece of the puzzle. Some subtypes react differently to certain therapies, and can even change subtypes in response to a therapy, meaning the treatment or approach may need to change to stay ahead of the cancer.

Ultimately, our goal is to provide physicians and life science companies with clear information about each GBM's subtype, to enable them to make the best decisions possible.

There are over 150 different companies developing treatments for GBM.

Our goal is to use expertise in Glioblastoma, subtyping, and searching for response signatures to identify which therapeutics match with each one of the four GBM subtypes to potentially improve clinical outcomes.

There are over 150 different companies developing treatments for GBM.Our goal is to use expertise in Glioblastoma, subtyping, and searching for response signatures to identify which therapeutics match with each one of the four GBM subtypes to potentially improve clinical outcomes.

There are over 150 different companies developing treatments for GBM.

Our goal is to use expertise in Glioblastoma, subtyping, and searching for response signatures to identify which therapeutics match with each one of the four GBM subtypes to potentially improve clinical outcomes.